Table 3 Baseline Montgomery Åsberg Depression Rating Scale (MADRS) scores and change in the depressive symptoms over 52 weeks for patients in the intention-to-treat and per-protocol analysis. Results are adjusted for additional specialized help from mental health services during the first 3 months. Values are means unless stated otherwise. Estimated mean differences and 95% CIs are presented.
Intention-to-treat MADRS (n = 181) | |||||
|---|---|---|---|---|---|
Usual care + paroxetine (n = 85) | Usual care (n = 96) | Mean difference* | SD | 95% CI | |
Baseline score | 23.8 | 24.2 | |||
6 weeks – baseline† | -7.7 | -5.8 | -1.9 | 20.7 | -5.0; 1.2 |
13 weeks – baseline † | -10.9 | -8.4 | -2.5 | 23.4 | -6.1; 1.1 |
26 weeks – baseline † | -13.1 | -10.1 | -3.0 | 21.4 | -6.4; 0.3 |
52 weeks – baseline † | -14.8 | -12.7 | -2.1 | 24.2 | -6.2; 1.9 |
Per-protocol MADRS (n = 133) | |||||
Usual care + paroxetine (n = 55) | Usual care (n = 78) | Mean difference* | SD | 95% CI | |
Baseline score | 25.2 | 24.1 | |||
6 weeks-baseline† | -8.2 | -6.5 | -1.7 | 22.1 | -5.5; 2.1 |
13 weeks-baseline† | -13.3 | -8.7 | -4.6 | 24.3 | -8.9; -0.3‡ |
26 weeks-baseline† | -14.0 | -9.3 | -4.8 | 20.6 | -8.5; -1.0‡ |
52 weeks-baseline† | -17.7 | -12.5 | -5.2 | 21.2 | -9.2; -1.2‡ |